Short answer
Coherus Oncology, Inc. (CHRS) filed an 8-K current report with the SEC on June 15, 2026 reporting Item 4.01 (Changes in Registrant's Certifying Accountant). EY dismissed June 12, 2026 as independent auditor.
- This filing includes Item 4.01, an item that often signal trouble.
Coherus Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 4.01 · Changes in Registrant's Certifying Accountant
- EY dismissed June 12, 2026 as independent auditor
- EY audit reports for fiscal years 2025 and 2024 contained no adverse, disclaimer, or qualified opinions
- No accounting disagreements or reportable events with EY, aside from a 2024 material weakness later remediated
- PwC selected for fiscal year ending December 31, 2026, subject to client acceptance
- Auditor transition appears administrative, with no disclosed dispute or unresolved control deficiency
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Coherus Oncology, Inc. 8-K filings
Get the next CHRS 8-K as it lands
Follow CHRS for push alerts, or ask the research agent what this filing means.